|
(Health-NewsWire.Net, June 11, 2015 ) Global Markets Direct’s, ‘Mild Cognitive Impairment – Pipeline Review, H1 2015′, provides an overview of the Mild Cognitive Impairment’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mild Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Inquire more about this Report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=390970 . (This is a premium report price at US$2000 for a single user PDF license)
Scope:
• Coverage of the Mild Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews key players involved in the therapeutics development for Mild Cognitive Impairment and enlists all their major and minor projects
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=390970 . (This is a premium report price at US$2000 for a single user PDF license)
Reasons to Buy:
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
More reports on Alzheimer Drugs Market :
Donepezil – Comprehensive patent search
Used by the world’s leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won’t need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on your business, rather than getting bogged down in patent data.
Complete report is available at http://www.rnrmarketresearch.com/donepezil-comprehensive-patent-search-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
